Almac Sciences has completed a $7.1 m investment in a two-storey centre for biocatalysis, flow chemistry technologies and peptide research and development.
Over the last 5 years, the company has made investments in its non-GMP and GMP manufacturing plants to support increased client manufacturing demands. Additionally, the first phase of expansion for technology development has been completed with the opening of a this facility housing additional R&D scientists to develop technology and projects for Almac’s established biocatalysis, flow chemistry and peptides businesses. Capacity has also been created to enable further growth of its chemical development offering.
The 2,000 sqm, two-storey dedicated technology centre is located at Almac Group’s global headquarter campus and consists of 32 fume hoods, an engineering workshop for tooling and has capacity to accommodate up to 100 employees. Active recruitment for 20 additional staff members is underway and with a number of projects already commenced.
The news follows Almac’s recent announcement of a multi-million pound investment to further develop a program to establish IN Silico Informed metaGenomic Harvesting Technology (INSIGHT).
Professor Tom Moody, VP Technology Development and Commercialisation, Almac Sciences and Arran Chemical Company said: “The investment in this new, state-of-the-art facility has been critical to support the rapid expansion of our innovative technology offering across different disciplines. As our technology evolves, we are experiencing an ever-increasing pipeline of projects taking advantage of our integrated offering from development through to manufacture. It is an exciting time to be at Almac as our technology success breeds success. We look forward to driving innovation for our clients in this new centre.”
